Histogen is one of RepliCel's top competitors. Histogen was founded in 2007 in San Diego, California. Like RepliCel, Histogen also operates in the Biotechnology industry. Histogen generates $255.7K less revenue than RepliCel.
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 202...
Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-...
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-b...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 202...
Frequently Asked Questions about RepliCel
Who are RepliCel's top competitors?
RepliCel's top 3 competitors are Histogen, Kolon TissueGene, Bonetherapeutics.
Who is similar to RepliCel?
Histogen is the most similar to RepliCel. Kolon TissueGene and Bonetherapeutics are also similar to RepliCel.
Are RepliCel and Histogen competitors?
Yes, Histogen is one of RepliCel’s top competitors.